Revance Therapeutics (RVNC) Misses Q4 EPS by 18c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
Revance Releases Fourth Quarter and Full Year 2018 Results
February 26, 2019 4:05 PM EST-Successful 2018: Positive SAKURA 3 topline data, Fosun and Mylan partnerships signed-
-On track to complete BLA submission with U.S. FDA for glabellar lines indication in the first half of 2019-
-Raised approximately $108 million net proceeds from public stock offering on January 22, 2019-
NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced results for the fourth quarter and full year ended December 31, 2018 and provided a business update.
Recent Highlights for... More
